Petrelintide (ZP8396)
Metabolic Health · Amylin analog
Tier C+
Bottom line
Read Off Label grades Petrelintide (ZP8396) as C+ (5.7/10) based on moderate evidence, med-high benefit magnitude, and a med-risk safety profile.
Roche/Zealand Pharma long-acting amylin analog.
Studied, labeled, or reported-use context: SC once weekly; escalated to a maintenance dose over ~16 wk in Phase 2 — Investigational; not individualized guidance.
What the evidence says
Roche/Zealand Pharma long-acting amylin analog. Phase 2 ZUPREME-1 (n=485; US/Poland/Romania) presented at ADA 2026: up to 10.7% body-weight loss vs 1.7% placebo at week 42 (p<0.001); 88-98% reached target maintenance dose; nausea 19.6% (>75% mild), only 1.5% discontinued for GI events. Amylin monotherapy positioned as a better-tolerated alternative or combination partner to GLP-1 agonists. Phase 3 for chronic weight management planned H2 2026. Industry-sponsored; conference data, peer-reviewed publication pending.
Mechanism
Long-acting amylin analog given once-weekly subcutaneously; promotes satiety and restores leptin sensitivity to curb food intake — an amylin-monotherapy approach to weight loss distinct from GLP-1 (incretin) agonists
Studied, labeled, or reported dose & route
SC once weekly; escalated to a maintenance dose over ~16 wk in Phase 2
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Petrelintide (ZP8396)'s effects?
- Read Off Label rates the evidence for Petrelintide (ZP8396) as Moderate and the benefit magnitude as med-high, producing an overall grade of C+ (5.7/10). Roche/Zealand Pharma long-acting amylin analog.
- What safety findings are reported for Petrelintide (ZP8396)?
- Petrelintide (ZP8396) has a med risk profile in the database. Med (dose-dependent GI: nausea ~20%, mostly mild; low GI-related discontinuation ~1.5%) Legal status: Investigational (Phase 3 planned H2 2026).
- What doses or routes are reported for Petrelintide (ZP8396)?
- SC once weekly; escalated to a maintenance dose over ~16 wk in Phase 2 This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Petrelintide (ZP8396) work?
- Long-acting amylin analog given once-weekly subcutaneously; promotes satiety and restores leptin sensitivity to curb food intake — an amylin-monotherapy approach to weight loss distinct from GLP-1 (incretin) agonists
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.